Methylprednisolone aceponate in eczema and other inflammatory skin disorders - A clinical update

International Journal of Clinical Practice

Volumn 60, Issue 1, 2006, Pages 85-92

  Ruzicka, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Eczema; Lipophilicity; Methylprednisolone aceponate; Paediatric; Topical corticosteroid

Indexed keywords

BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; HYDROCORTISONE BUTYRATE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PIMECROLIMUS; PREDNICARBATE; TACROLIMUS; ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; METHYLPREDNISOLONE;

ALLERGIC REACTION; ARTICLE; CLINICAL TRIAL; CREAM; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG SOLUTION; DRUG STRUCTURE; DRUG TOLERABILITY; ECZEMA; FACE DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; OINTMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; PSORIASIS; RELIABILITY; SKIN ATROPHY; SKIN DISEASE; SKIN INFLAMMATION; SKIN IRRITATION; SUNBURN; TELANGIECTASIA; DERMATITIS; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; DERMATITIS; DERMATOLOGIC AGENTS; ECZEMA; FACIAL DERMATOSES; HUMANS; METHYLPREDNISOLONE; PSORIASIS; SCALP DERMATOSES; SUNBURN; TREATMENT OUTCOME;

EID: 33644833823     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00754.x     Document Type: Article

References (35)

1. Benton EC, Hunter JA. The dermatology out-patient service. a study of out-patient referrals in a Scottish population. Br J Dermatol 1984; 110: 195-201.
2. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994; 30: 35-9.
3. Sugiura H, Uchiyama M, Omoto M et al. Prevalence of infantile and early childhood eczema in a Japanese population: Comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1997; 77: 52-3.
4. Christie GL, McDougall CM, Helms PJ. Is the increase in asthma prevalence occurring in children without a family history of atopy? Scott Med J 1998; 43: 180-2.
5. Zaumseil R-P, Fuhrmann H, Kecskés A et al. Methylprednisolone aceponate (Advantan®) - an effective topical corticoid therapy with few side effects. Jahrbuch der Dermatologie 1992; 3: 247-63.
6. Kecskés A, Jahn P, Matthes H et al. Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers. J Am Acad Dermatol 1993; 28: 789-92.
7. Fritsch P. Clinical experience with methylprednisolone ace-ponate (MPA) in eczema. J Dermatolog Treat 1992; 3 (Suppl. 2): 17-9.
8. Albrecht G. Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema. J Eur Acad Dermatol Venereol 1994; 3 (Suppl. 1): S42-8.
9. Toepert M, Olivar A, Opitz D. New developments in corticosteroid research. J Dermatolog Treat 1990; 1 (Suppl. 3): S5-9.
10. Haria M, Balfour A. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. Clin Immunother 1995; 3: 241-53.
11. Täuber U. Pharmacokinetics and bioactivation of MPA. J Eur Acad Dermatol Venereol 1994; 3 (Suppl. 1): 23-31.
12. Zentl HJ, Toepert M. Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate. J Eur Acad Dermatol Venereol 1994; 3 (Suppl. 1): 32-8.
13. Miller JA, Munro DD. Topical corticosteroids: Clinical pharmacology and therapeutic use. Drugs 1980; 19: 119-34.
14. Kecskés A, Jahn P, Wendt H et al. Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers. Arzneimittelforschung 1993; 43: 144-7.
15. Schäfer-Korting M, Schmid MH, Korting HC. Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Saf 1996; 14: 375-85.
16. Mensing H, Lorenz B. Experience with methylprednisolone aceponate (MPA) in patients suffering from acute and chronic eczema. Results of a large observational study. Z Hautkr 1998; 73: 281-5.
17. Ortonne JP. Skin atrophogenic potential of methylprednisolone acetate (MPA). J Eur Acad Dermatol Venereol 1994; 3 (Suppl. 1): S13-8.
18. Mori M, Pimpinelli N, Giannotti B. Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio. Drug Saf 1994; 10: 406-12.
19. Haneke E. Long-term treatment with 6-alpha methylprednisolone aceponate. J Eur Acad Dermatol Venereol 1994; 3 (Suppl. 1): S19-22.
20. Kecskés A, Jahn P, Lange L. Local tolerability of topically applied methylprednisolone aceponate. J Am Acad Dermatol 1993; 28 (5 Part 1): 786-8.
21. Kecskés A, Heger-Mahn D, Kleine-Kuhlmann R, Lange L. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol 1993; 29: 576-80.
22. Rampini E. Methylprednisolone aceponate (MPA) - use and clinical experience in children. J Dermatol Treat 1992; 3 (Suppl. 2): 27-9.
23. Casano AV, Cavalle JR. The milk formulation in topical corticotherapy: outcomes in children with atopic dermatitis. Monografia de Dermatologia 2002; XV: 399-408.
24. Korotky NG, Taganov AV. The use of steroid Advantan (methylprednisolone aceponate) for management of allergodermatoses in children. Vestn Dermatol Venereol 2000; 3: 61-3.
25. Soennichsen N, Mekbib K. Die behandlung des atopischen ekzems (neurodermitis) im kindesalter mit 6-alpha-methylprednisoloneaceponat [in German]. Der Deutsche Dermatologe 1996; 44: 8.
26. Ruzicka T, Zaumseil RP. Effectiveness and tolerability of methylprednisolone aceponate (Advantan®) in the treatment of eczematous disorders of the face. Z Hautkr 2002; 77: 185-9.
27. Soennichsen N, Zaumseil RP. Efficacy and tolerability of methylprednisolone aceponate solution in eczematous disease of the hairy scalp. Derm 1999; 5: 317-24.
28. Duteil L, Queille-Roussel C, Lorenz B et al. A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers. Clin Exp Dermatol 2002; 27: 314-8.
29. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25: 1-10.
30. Van de Kerkhof PC. The management of psoriasis. Neth J Med 1998; 52: 40-5.
31. Geilen CC, Orfanos CE. Standard and innovative therapy of psoriasis. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S81-7.
32. Wozel G. Topical therapy of psoriasis vulgaris in children and young adults. Soz Padiatr Kinderarztl Prax 1996; 18: 4.
33. Filimonkova NN, Kungurov NV. Use of different pharmaceutical forms of Advantan (methylprednisolone aceponate) for combined treatment of patients with psoriasis [in Russian]. Vestn Dermatol Venereol 2002; 2: 49-50.
34. Tarim G, Cantuerk T, Sentuerk N et al. The clinical assessment of calcipotriol and methylprednisolone aceponate ointments in treatment of psoriasis vulgaris [in Russian]. Ondokuz Mayis Universitesi Tip Dergisi 2000; 17: 240-5.
35. Luger TA. Topical dermatotherapy with glucocorticoids - therapeutic index. Guidelines of the German Dermatology Society. AWMF 2003.